WHO Drug Information Vol. 24, No. 4, 2010

More documents

Recommendations

Info

Proposed INN: List 104 WHO Drug Information, Vol. 24, No. 4, 2010urelumabum #urelumaburélumaburelumabimmunoglobulin G4-kappa, anti-[Homo sapiens TNFRSF9 (tumornecrosis factor receptor superfamily member 9, 4-1BB, T cell antigenILA, CD137)], Homo sapiens monoclonal antibody;gamma4 heavy chain (1-448) [Homo sapiens VH (IGHV4-34*01(92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 hingeS10>P (229) (122-448)], (135-216')-disulfide with kappa light chain(1'-216') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; (227-227'':230-230'')-bisdisulfide dimerimmunomodulatorimmunoglobuline G4-kappa, anti-[Homo sapiens TNFRSF9 (membre9 de la superfamille des récepteurs du facteur de nécrose tumorale,4-1BB, antigène ILA de lymphocyte T, CD137)], Homo sapiensanticorps monoclonal;chaîne lourde gamma4 (1-448) [Homo sapiens VH (IGHV4-34*01(92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 charnièreS10>P (229) (122-448)], (135-216')-disulfure avec la chaîne légèrekappa (1'-216') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; dimère(227-227'':230-230'')-bisdisulfureimmunomodulateurinmunoglobulina G4-kappa, anti-[TNFRSF9 de Homo sapiens(miembro 9 de la superfamilia de receptores del factor de necrosistumoral, 4-1BB, antígeno ILA de linfocito T, CD137)], anticuerpomonoclonal de Homo sapiens;cadena pesada gamma4 (1-448) [Homo sapiens VH (IGHV4-34*01(92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 bisagraS10>P (229) (122-448)], (135-216')-disulfuro con la cadena ligerakappa (1'-216') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; dímero(227-227'':230-230'')-bisdisulfuroinmunomodulador934823-49-1Heavy chain / Chaîne lourde / Cadena pesadaQVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQS PEKGLEWIGE 50INHGGYVTYN PSLESRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARDYG 100PGNYDWYFDL WGRGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD 250TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK 448Light chain / Chaîne légère / Cadena ligeraEIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPALTF 100CGGTKVEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW 150KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH 200QGLSSPVTKS FNRGEC 216Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-95 148-204 262-322 368-42622''-95'' 148''-204'' 262''-322'' 368''-426''Intra-L 23'-88' 136'-196'23'''-88''' 136'''-196'''Inter-H-L 135-216' 135''-216'''Inter-H-H 227-227'' 230-230''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación298, 298''398
WHO Drug Information, Vol. 24, No. 4, 2010 Proposed INN: List 104usistapidumusistapideusistapideusistapidamethyl (2S)-2-phenyl-2-[4-(4-{4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido}phenyl)piperidin-1-yl]acetateantihyperlipidaemic(+)-(2S)-2-phényl-2-{4-[4-({[4'-(trifluorométhyl)-[1,1'-biphényl]-2-yl]carbonyl}amino)phényl]pipéridin-1-yl}acétate de méthyleantihyperlipidémiant(2S)-2-fenil-2-[4-(4-{4'-(trifluorometil)-[1,1'-bifenil]-2-carboxamido}fenil)piperidin-1-il]acetato de metiloantihiperlipémicoC 34 H 31 F 3 N 2 O 3 403989-79-7CF 3NHOCH 3OONHvesencumabum #vesencumab immunoglobulin G1-kappa, anti-[Homo sapiens NRP1 (neuropilin 1,NRP, vascular endothelial cell growth factor 165 receptor, VEGF165receptor, VEGF165R, CD304) extracellular domain], Homo sapiensmonoclonal antibody;gamma1 heavy chain (1-453) [Homo sapiens VH (IGHV3-23*04(90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3D12>E (362), L14>M (364) (124-453)], (226-214')-disulfide withkappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01(89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (232-232'':235-235'')-bisdisulfide dimerantineoplasticvésencumabimmunoglobuline G1-kappa, anti-[Homo sapiens NRP1 (neuropiline1, NRP, récepteur de l'isoforme 165 du facteur de croissance descellules endothéliales vasculaires, récepteur du VEGF165,VEGF165R, CD304) domaine extracellulaire], Homo sapiensanticorps monoclonal;chaîne lourde gamma1 (1-453) [Homo sapiens VH (IGHV3-23*04(90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3D12>E (362), L14>M (364) (124-453)], (226-214')-disulfure avec lachaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')];dimère (232-232'':235-235'')-bisdisulfureantinéoplasique399
Page 1 and 2:
WHO Drug Information Vol. 24, No. 4
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58: WHO Drug Information Vol. 24, No. 4
Page 59 and 60: WHO Drug Information Vol. 24, No. 4
Page 61 and 62: WHO Drug Information, Vol. 24, No.
Page 107: WHO Drug Information, Vol. 24, No.
show all

WHO Drug Information Vol. 24, No. 4, 2010

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?